The US Just Added Microplastics to Its Official Drinking Water Candidate List — Here Is What That Actually Changes

On April 2, 2026, the US Environmental Protection Agency released its draft Sixth Contaminant Candidate List — CCL 6 — and for the first time placed microplastics in it as a priority contaminant group. Pharmaceuticals were also added as a group for the first time. The Contaminant Candidate List identifies substances in drinking water not yet regulated under the Safe Drinking Water Act, but that warrant research and potential future consideration. The CCL itself does not impose any requirements on public water systems.

The same day, the Department of Health and Human Services launched a $144 million programme called STOMP — Systematic Targeting Of MicroPlastics — through ARPA-H, the Advanced Research Projects Agency for Health. Its goal is to develop tools to measure, understand, and in a later phase, remove microplastics from the human body.

What the CCL Actually Does — and Does Not Do

Being placed on the Contaminant Candidate List is the very first step in a long regulatory process under the Safe Drinking Water Act. The CCL prioritises research and funding. It does not ban, limit, or require removal of anything from drinking water. In five previous cycles of this process since 1996, the EPA determined that no regulatory action was needed for most of the contaminants examined. The first substances ever to move from a CCL to actual regulated limits were certain PFAS compounds — and that only happened in 2024, under the Biden administration.

Erik Olson, a senior attorney at the Natural Resources Defense Council who works on drinking water protection, described the announcement as “the beginning of a very long process that routinely ends in nothing.” At the same time, Judith Enck, a former EPA regional administrator who now leads Beyond Plastics, called inclusion on the list “the first step toward eventually regulating microplastics in public water supplies — and hopefully not the last.”

Critics also flagged a contradiction: while the EPA announced this new CCL, the same administration is simultaneously seeking to roll back Biden-era limits on four PFAS “forever chemicals.” An environmental attorney described this as “a classic bait and switch” — adding contaminants to a watchlist while weakening protections already set for others.

What STOMP Will Actually Do

STOMP is led by ARPA-H programme managers Dr. Ileana Hancu and Dr. Shannon Greene. It operates in two phases. Phase one focuses on measurement and biological mechanisms — developing gold-standard clinical tests that can accurately quantify a person’s microplastic burden across tissues. Current measurement techniques produce inconsistent results between labs, which makes it difficult to assess actual health risk with precision. The CDC will serve as an independent validator of the methods developed.

Phase two will focus on removal — drawing on pharmaceutical biology and bioremediation science to develop ways to safely extract microplastics from living human tissue. ARPA-H Director Dr. Alicia Jackson described the challenge plainly: “Microplastics are in every organ we look at — in ourselves and in our children. But we don’t know which ones are harmful or how to remove them. The field is working in the dark. STOMP is turning on the lights.”

STOMP will also produce a risk stratification mechanism — a ranking of which plastic polymers are most biologically harmful — to help scientists, regulators, and industry agree on which types need to be addressed first. Full proposals for the programme are due June 22, 2026.

Why This Matters in India — Especially in Cities Like Mumbai

While this is a US regulatory announcement, the underlying science is global — and the numbers from India are significant. A 2022 study published in Environmental Research that sampled drinking water, respirable air, and cooked food in Mumbai estimated an average daily exposure of approximately 2,012 microplastic particles per person. Food was the dominant route of exposure, followed by air, then water. The major polymers identified in the food samples were polyethylene terephthalate, polystyrene, polynorbornene, nylon, polychloroprene, and copolymer polyacrylamide.

A 2026 peer-reviewed study on Indian drinking water found that non-commercially bottled water brands contained an average of 212 microplastic particles per litre — substantially higher than tap water samples, which ranged from 4.3 to 60 particles per litre. Portable devices for rapid microplastic detection in water are now being developed that could reach affordable price points — but the regulatory gap in India remains wide.

No microplastics-specific national monitoring or benchmark framework for drinking water has been identified in India, based on available sources. There is no process equivalent to the US Contaminant Candidate List for microplastics underway at the national level. The US action — however preliminary — at least establishes that formal monitoring is being considered. That national-level conversation has not begun in India in any comparable form.

The Bottled Water Paradox

One of the more counterintuitive findings in microplastics research: bottled water may expose people to significantly more microplastics than tap water. Research published in Environmental Science and Technology estimates that people who meet their daily water intake entirely through bottled sources may ingest approximately 90,000 additional microplastic particles per year compared to roughly 4,000 for those who drink only tap water. The plastic packaging itself is a primary source — abrasion from bottle caps and the bottling process leach particles directly into the water.

This is directly relevant for cities like Mumbai, where bottled water consumption is driven by declining trust in tap water quality. In 2021, Mumbai was among the highest consumers of packaged bottled water in India. Switching to filtered tap water — using a quality filter — may reduce microplastic exposure more effectively than switching to bottled water.

Pharmaceuticals in Water — The Other Half of This Announcement

Microplastics drew the headlines, but CCL 6 also added pharmaceuticals to the candidate list for the first time — another category that conventional water treatment largely fails to remove. Pharmaceutical compounds enter the water supply because humans excrete them after taking medication, and standard wastewater treatment plants are not designed to remove them. EPA Administrator Lee Zeldin noted this at the announcement. The EPA simultaneously released non-enforceable human health benchmarks for 374 pharmaceutical compounds to help local water authorities assess risk — these benchmarks are not regulations and create no obligations for water systems on their own.

Related Coverage on KarmActive

The CCL 6 announcement sits alongside several parallel regulatory and scientific developments. Earlier this year, the EPA extended PFAS compliance deadlines and dropped limits on four forever chemicals. Separately, 73 million Americans remain exposed to PFAS levels above the Biden-era standards that the current administration is seeking to rescind. On the science side, research from the Max Planck Institute found that oceans absorb 15% of airborne microplastics, redirecting attention to land-based pollution sources. An IIT Madras study identified residential households as a major microplastics source — particularly synthetic fibres and personal care products. A portable device developed at the University of British Columbia can now detect microplastics in water in 20 minutes at a per-test cost of 1.5 cents. And the Beyond Plastics report on toxic PVC water pipes remains relevant — the materials carrying water to homes can themselves be a source of plastic contamination.

The EPA’s CCL 6 announcement placed microplastics and pharmaceuticals on a formal federal watchlist for the first time in the programme’s history. The STOMP programme committed $144 million toward understanding how microplastics accumulate in the human body and, in a later phase, developing ways to remove them. Public comments on the draft CCL 6 must be received by June 5, 2026 via docket EPA-HQ-OW-2022-0946 at regulations.gov, with finalisation expected by November 17, 2026. These actions were described by EPA and HHS as a landmark step. Independent experts and advocacy groups noted they sit within a regulatory process that has historically moved slowly and frequently concluded without binding outcomes.